<?xml version="1.0" encoding="UTF-8"?>
<p>The primary objective of the clinical trial was to demonstrate the noninferiority of BNO 1045 for 7 days of treatment versus a single dose of FT in women with acute lower uUTIs, as measured by the proportion of patients who received an additional antibiotic for acute lower uUTIs during the trial until the follow-up visit [
 <xref rid="B5" ref-type="bibr">5</xref>]. Secondary efficacy endpoints included clinical assessment by the ACSS questionnaire, as well as bacteriuria and leukocyturia based on the results of urinalysis and culture (midstream sample) at each on-site visit.
</p>
